Synlogic, Inc., (Nasdaq: SYBX) announced that it is discontinuing development of SYNB1020, an early stage clinical product candidate for the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE